Companion Animal Arthritis Market Report: Market Size & Forecast 2026

The companion animal arthritis market encompasses treatments and management solutions for osteoarthritis and related musculoskeletal conditions affecting household pets. With a 2025 valuation near $3.6 billion, the market addresses a substantial and growing veterinary healthcare need across companion animal species. Product offerings range from non-steroidal anti-inflammatory drugs and injectable therapies to joint supplements containing glucosamine and chondroitin, as well as physical rehabilitation and orthopedic devices.

• •Market valued at approximately $3.6 billion in 2025 with a projected 7.2% CAGR through 2033-2034
• •Primary species addressed are dogs and cats, with dogs representing the largest segment due to higher osteoarthritis prevalence
• •Treatment categories include pharmaceuticals, nutraceuticals/supplements, therapeutic diets, and veterinary medical devices

The humanization of pets is a dominant trend, with owners increasingly willing to invest in advanced veterinary care and pain management for aging companion animals. Rising pet adoption rates and the growing population of geriatric pets, who are more prone to degenerative joint disease, are expanding the addressable patient base. Advances in veterinary medicine, including novel biologic therapies and improved diagnostic imaging, are also creating new treatment opportunities and supporting premium product demand.

• •Increasing pet humanization driving higher willingness to pay for advanced veterinary therapeutics and chronic disease management
• •Growing geriatric pet population worldwide, as improved nutrition and care extend companion animal lifespans
• •Expanding availability of innovative treatments such as monoclonal antibodies, regenerative therapies, and advanced NSAIDs

The market is segmented by animal type, with dogs commanding the majority share due to their higher susceptibility to osteoarthritis and larger population of working and athletic breeds. By treatment modality, the market includes pharmaceutical drugs, nutraceutical supplements, therapeutic diets, and medical devices, each serving different stages of disease severity and owner preference. Geographically, North America leads in market share due to high pet ownership, advanced veterinary infrastructure, and favorable reimbursement trends, while Europe and the Asia-Pacific region represent significant and growing markets driven by rising disposable incomes and expanding companion animal healthcare sectors.

• •Dogs represent the dominant animal type segment, while cats constitute a smaller but notable share of the market
• •Treatment segmentation includes NSAIDs, injectable disease-modifying osteoarthritis drugs, supplements, and rehabilitation solutions
• •North America holds the largest regional share, with Europe and Asia-Pacific emerging as high-growth regions

What are the recent trends and outlook?

The market is experiencing a shift toward targeted, disease-modifying therapies, including monoclonal antibodies and regenerative medicine approaches that address underlying joint pathology rather than merely managing symptoms. Pet owners and veterinarians are increasingly adopting multimodal management strategies that combine pharmaceutical interventions with weight management, physical rehabilitation, and nutritional support. As veterinary medicine continues to advance and companion animals enjoy longer lifespans, the arthritis market is expected to sustain robust growth through 2033 and beyond, supported by new product launches and expanding global adoption of companion animal healthcare services.

• •Monoclonal antibody therapies and regenerative medicine represent emerging high-growth product categories targeting underlying disease mechanisms
• •Multimodal treatment protocols combining pharmaceuticals, supplements, diet, and rehabilitation are gaining veterinary practitioner acceptance
• •Long-term market outlook remains positive through 2033-2035, supported by aging pet populations, product innovation, and expanding global veterinary care access